Searchable abstracts of presentations at key conferences in endocrinology

ea0032p30 | Adrenal cortex | ECE2013

Patients with Addison’s disease have increased frequency of the metabolic syndrome: a case–control study

Bergthorsdottir Ragnhildur , Ragnarsson Oskar , Johannsson Gudmundur

Background: Patient’s with Addison’s disease (AD) have increased morbidity and mortality. Cardiovascular disease is considered the leading cause of death. The aim was to study cardiovascular risk factors in patients with AD.Methods: In a single-centre, case–ontrol study 78 patients (52 women) with AD were compared to 78 controls, matched for gender, age, BMI, and smoking habits. Serum was collected in a fasting state for measurement of lip...

ea0014oc8.6 | Neuroendocrinology clinical | ECE2007

Improved glucocorticoid replacement therapy by a novel oral hydrocortisone modified-release tablet

Skrtic Stanko , Lennernäs Hans , Nilsson Anna , Bergthorsdottir Ragnhildur , Hedner Thomas , Johannsson Gudmundur

Background: Mortality rate in patients with primary and secondary adrenal insufficiency is increased. A contributing factor could be the dose and the pattern of glucocorticoid replacement therapy. Hydrocortisone administered twice or thrice daily produces high serum peaks and low trough values in-between. A novel, once daily, hydrocortisone modified release tablet with combined immediate and extended release characteristics was developed.Purpose: The aim...

ea0014oc12.5 | Diabetes | ECE2007

The influence of concomitant diabetes mellitus on mortality in Addison’s disease

Bergthorsdottir Ragnhildur , Leonsson-Zachrisson Maria , Odén Anders , Johannsson Gudmundur

Background: The prevalence of type 1 diabetes mellitus (DM) among patients with primary adrenal insufficiency (Addison’s disease) is 3-4 times higher than the expected prevalence in the population. The mortality rate due to DM is more than 3-fold the mortality rate in the background population. The impact of DM on mortality rate in patients with Addison’s disease is not known.Objectives: To study the frequency of DM and its impact on mortality ...

ea0063gp157 | Cushing's | ECE2019

DNA Methylation and fMRI responses in patients with Cushing’s syndrome in remission – suggestions of a functional link between hypercortisolism and neurocognitive dysfunction

Glad Camilla , Andersson-Assarsson Johanna , Stomby Andreas , Dahlqvist Per , Nyberg Lars , Bergthorsdottir Ragnhildur , Johannsson Gudmundur , Ragnarsson Oskar

Introduction: Compared with healthy controls, women with Cushing’s syndrome (CS) in long-term remission have reduced functional brain responses during episodic and working memory testing and decreased overall levels of DNA methylation in blood cells. Here, we sought to test the hypothesis that functional brain responses in the prefrontal cortex and hippocampus are related to epigenetic changes in subjects with CS in long-term remission.Methods: In t...

ea0041gp14 | Adrenal (1) | ECE2016

A Phase 3b, open-label, extension study to evaluate the long-term safety of once-daily, dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI)

Nilsson Anna , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Eden Engstrom Britt , Ragnarsson Oskar , Skrtic Stanko , Wahlberg Jeanette , Achenbach Heinrich , Uddin Sharif , Marelli Claudio , Johannsson Gudmundur

Introduction: Glucocorticoid replacement for adrenal insufficiency (AI) remains inadequate, resulting in high morbidity, premature mortality and quality-of-life (QoL) impairment. This study investigated the long-term safety of dual-release hydrocortisone (DR-HC) in patients with primary AI.Methods: AI patients who completed a randomized, 3-month crossover study of once-daily DR-HC versus thrice-daily conventional immediate-release hydrocortisone plus a 6...

ea0056gp30 | Adrenal clinical | ECE2018

The urinary cortisol metabolome in patients with adrenal insufficiency: dual-release hydrocortisone is less deleterious than conventional hydrocortisone therapy

Espiard Stephanie , McQueen Johanna , Sherlock Mark , Ragnarsson Oskar , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Engstrom Britt Eden , Nilsson Anna G , Skrtic Stanko , Wahlberg Jeanette , Stewart Paul M , Johannsson Gudmundur

Introduction: Oral once-daily dual-release hydrocortisone (DR-HC) therapy provides a more physiological cortisol profile than conventional thrice-daily (TID) replacement therapy and has demonstrated improved metabolic profile among patients with adrenal insufficiency (AI). The mechanisms by which this metabolic improvement occurs may be due to less total exposure, changed cortisol time exposure profile, but also modified metabolism of cortisol.Objective:...

ea0056p160 | Steroid metabolism + action | ECE2018

Urinary steroid profile in patients with primary adrenal insufficiency under conventional glucocorticoid replacement: a case control study

Espiard Stephanie , McQueen Johanna , Ragnarsson Oskar , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Eden Engstrom Britt , Nilsson Anna G. , Skrtic Stanko , Wahlberg Jeanette , Sherlock Mark , Stewart Paul M. , Johannsson Gudmundur

Introduction: Primary adrenal insufficiency (PAI) leads to a drastically reduced production of steroids from the adrenal cortex, but a few patients may keep some residual adrenal steroid secretion that may simplify replacement therapy and prevent adrenal crisis. Irrespectively, the conventional glucocorticoid (GC) replacement therapy, using thrice-daily oral hydrocortisone, does not restore the patients’ physiological cortisol profile.Objective: The...